fda tirzepatide compound approval Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro FDA confirms tirzepatide shortage is

CDNA for the multidrug resistance (MDR-1) gene in a transcription unit of a safety modified retrovirus confers in vivo resistance to Taxol on early precursor cells in a mouse transplant model and on long-term human marrow culture

Lifestyle effects on aging and CVD: A spotlight on the nutrient-sensing network

262,263 Additionally, substituting dietary SFAs with monounsaturated fatty acids improves nerve function in HFD mice without significantly altering plasma metabolic profiles, suggesting that dietary fats influence neuropathy development

The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)

Compared to brand-name GLP-1 medications at retail price ($13,000 to $16,000 per year for Wegovy or Mounjaro without insurance), Mochi's compounded options represent substantial savings